3rd Annual European Medical Device Reimbursement Conference

Moving Toward a Unified Reimbursement Process across Europe through the Creation of Specific Pathways for New & Existing Medical Technologies, while Meeting Increasing Clinical Data Requirements and Maximizing Positive HTA Decisions

January 23-24, 2012 | Brussels, Belgium

Throughout Europe, medical device corporations are working towards integrating new technologies as quickly and as effectively as possible. As the market has continued to expand, executives are continually looking to find new strategies for addressing the myriad delays and set-backs that they face in bringing these products onto the market. While a unified system is far from coming into reality, manufacturers are striving to set a single pathway for gaining reimbursement for their new and existing product offerings.

A key strategy that will be discussed during this program is setting that single pathway for successfully integrating new products into the market. Rather than delving into specific case studies examining each individual country or market, case studies will examine specific products that have seen wild successes in their integration processes. Through the careful discussion and debate surrounding these product success stories, executives will have a far more thorough understanding of what needs to be accomplished within their own organizations in order to match these successes.

As with all Q1 programs, a considerable mix of presenters including top-industry executives alongside regulatory bodies and other experts will allow this program to meet the educational requirements of participants. With seamlessly melded formal and informal networking opportunities, the focus will not singularly lie on educational aspects, but also networking, informal knowledge share and relationship building across the industry.

TOPICS TO BE COVERED

Opportunities in Creating a Single Approach to Reimbursement for Multiple Markets
Reimbursement of Medical Devices in European Countries: When and How Clinical and Economic Data Support Access to Additional Funds
Overcoming Limitations in Randomized Controlled Trials to Support Access
Panel Discussion: Successfully Exhibiting Evidence to Obtain Reimbursement of an Innovative Device
Best Practices in Planning For Reimbursement in Europe
Examining Trends within Major European Market HTAS
Forecasting Benefits in the EUnetHTA Joint Action
Best Practices: Overcoming Challenges in the Integration of Innovative Devices in Germany, France & the UK
NHS Reform: Impact on Medical Device Reimbursement
Examining the Vision of the EuroDRG Project
Recognizing Challenges in Cross-Border Reference Pricing Trends in Europe
Effective Training of Sales Teams on Reimbursement Processes
Pharmaceuticals vs. Medical Devices: Similarities and Differences in Securing Reimbursement
Legal Implications & Compliance in the Sales & Marketing of Medical Devices in Europe